Millennium Says Heavy R&D Costs, Acquisition Fees Offset Strong Revenue Growth in Q3 | GenomeWeb

NEW YORK, Oct. 15 - Millennium Pharmaceuticals today reported that a jump in R&D spending and the cost of acquiring Cor Therapeutics in February offset a surge in total revenue during the third quarter.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."